Is sotoracib a chemotherapy drug or a targeted drug for the treatment of lung cancer?

Sotorasib is a targeted drug that targets the KRAS G12C mutation rather than a traditional chemotherapy drug. Its mechanism of action and effect are significantly different from those of chemotherapy drugs. Chemotherapy inhibits the growth of cancer cells by non-specifically killing rapidly dividing cells, but it also affects normal, rapidly dividing cells in the body, such as blood cells, hair follicle cells, etc., causing a wide range of side effects. In contrast, targeted drugs are designed to more precisely target specific gene or protein mutations in cancer cells, thereby reducing the impact on normal cells.

In patients with non-small cell lung cancer (NSCLC), KRAS G12Cmutation is a relatively common genetic mutation, accounting for approximately 13% to 15% of all NSCLC patients. This mutation results in sustained activation of the KRAS protein, promoting cancer cell proliferation and tumor growth. Sotorasiib binds to the active site of the KRAS G12C mutated protein, inhibits its signal transduction, and blocks the growth signal transmission of tumor cells. The precision of this mechanism made sotorasib the first approved KRAS G12C mutation-targeting drug and demonstrated excellent efficacy in clinical trials.

Additionally, the side effects of sotoraxib are generally milder and more manageable. Common side effects include fatigue, diarrhea, nausea, and abnormal liver function, which can usually be controlled through dose adjustment or auxiliary drugs and will not cause extensive toxic effects like chemotherapy.

The emergence of sotorasiib provides a new, personalized treatment option for patients with KRAS G12C mutated non-small cell lung cancer, making targeted therapy a powerful alternative to chemotherapy. With the increasing application of targeted drugs in cancer treatment, more and more patients can benefit from targeted therapy and enjoy longer survival and better quality of life.